Zobrazeno 1 - 10
of 199
pro vyhledávání: '"Christine Theodore"'
Autor:
Valentina Orlando, Damien Drubay, Pernelle Lavaud, Laura Faivre, François Lesaunier, Remy Delva, Gwenaëlle Gravis, Frédéric Rolland, Frank Priou, Jean-Marc Ferrero, Nadine Houede, Loic Mourey, Christine Theodore, Ivan Krakowski, Jean-François Berdah, Marjorie Baciuchka, Brigitte Laguerre, Aude Fléchon, Marine Grosse-Goupil, Isabelle Cojean-Zelek, Stéphane Oudard, Jean-Luc Labourey, Paule Chinet-Charrot, Eric Legouffe, Jean-Léon Lagrange, Claude Linassier, Gaël Deplanque, Philippe Beuzeboc, Jean-Louis Davin, Anne-Laure Martin, Meryem Brihoum, Stéphane Culine, Gwénaël Le Teuff, Karim Fizazi
Publikováno v:
Clinical Genitourinary Cancer.
Autor:
Johann S. de Bono, Carole Helissey, Roberto Iacovelli, Bohuslav Melichar, Gero Kramer, Elizabeth M. Poole, Joan Carles, Christine Theodore, Aristotelis Bamias, Christian Wülfing, Ronald de Wit, Karim Fizazi, Jean-Christophe Eymard, Daniel Castellano, Ásgerður Sverrisdóttir, Susan Feyerabend, Christine Geffriaud-Ricouard, Ayse Ozatilgan, Bertrand Tombal, Cora N. Sternberg
Publikováno v:
European Urology, 80(4), 497-506. Elsevier
European Urology, Vol. 80, no. 4, p. 497-506 (2021)
European Urology, Vol. 80, no. 4, p. 497-506 (2021)
Background: In the CARD study (NCT02485691), cabazitaxel significantly improved median radiographic progression-free survival (rPFS) and overall survival (OS) versus abiraterone/enzalutamide in patients with metastatic castration-resistant prostate c
Autor:
Ronald de Wit, Gero Kramer, Carole Helissey, Roberto Iacovelli, Daniel Castellano, Susan Feyerabend, Stéphane Oudard, Bohuslav Melichar, Gaetano Facchini, Ayse Ozatilgan, Christian Wülfing, Christine Theodore, Ásgerður Sverrisdóttir, Johann S. de Bono, Christine Geffriaud-Ricouard, Bertrand Tombal, Samira Bensfia, Cora N. Sternberg, Karim Fizazi, M. Liontos, Jean-Christophe Eymard, Elizabeth M. Poole, Joan Carles
Publikováno v:
Lancet Oncology, 21(11), 1513-1525. Lancet Publishing Group
Lancet Oncology
Lancet Oncology, Elsevier, 2020, 21, pp.1513-1525. ⟨10.1016/S1470-2045(20)30449-6⟩
The Lancet Oncology, Vol. 21, no. 11, p. 1513-1525 (2020)
Lancet Oncology
Lancet Oncology, Elsevier, 2020, 21, pp.1513-1525. ⟨10.1016/S1470-2045(20)30449-6⟩
The Lancet Oncology, Vol. 21, no. 11, p. 1513-1525 (2020)
BACKGROUND: In the CARD study, cabazitaxel significantly improved radiographic progression-free survival and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with
Autor:
Elizabeth R. Plimack, Salvatore Lo Vullo, Guru Sonpavde, Ulka N. Vaishampayan, Sandy Srinivas, Matthew D. Galsky, Daniele Raggi, Joaquim Bellmunt, Patrizia Giannatempo, Jonathan E. Rosenberg, Aristotle Bamias, Luigi Mariani, Andrea Necchi, Simon J. Crabb, Evan Y. Yu, Guenter Niegisch, Srikala S. Sridhar, Thomas Powles, Christine Theodore, Dominik Berthold
Publikováno v:
Journal of Urology. 200:1207-1214
We evaluated the impact of the number of cycles of platinum based, first line chemotherapy (fewer than 6 cycles vs the conventional 6 cycles or more) on the survival of patients with metastatic urothelial carcinoma.We used the RISC (Retrospective Int
Autor:
Thomas Powles, Michiel S van der Heijden, Daniel Castellano, Matthew D Galsky, Yohann Loriot, Daniel P Petrylak, Osamu Ogawa, Se Hoon Park, Jae-Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J Eigl, Howard Gurney, Som D Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P Fay, Ignacio Duran, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok K Gupta, Wendy Levin, Joaquim Bellmunt, Michiel S. van der Heijden, Jae Lyun Lee, Bernhard J. Eigl, Som D. Mukherjee, Cristina Suarez, Hans Westgeest, Aude Flechon, Yen-Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez-Valderrama, Susanna Cheng, Stephen Frank, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala Sridhar, Giorgio Vittorio Scagliotti, Jens Voortman, Boris Alekseev, Anna Alyasova, Boris Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, Jose Angel Arranz, Djura Piersma, Sang Joon Shin, Oleg Karyakin, Ignacio Delgado, Jose Luis Gonzalez, See-Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, Monserrat Domenech, Yen-Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, Vasileios Georgoulias, Sasja Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott Tagawa, Pawel Zalewski, Florence Joly, Gencay Hatiboglu, Luca Gianni, Franco Morelli, Rosa Tambaro, Yasuhiro Hashimoto, Alexander Nosov, Albert Font, Alejo M. Rodriguez-Vida, Robert Jones, Naveen Vasudev, Sandhya Srinivas, Jingsong Zhang, Thierry Gil, Daygen Finch, Marc-Oliver Grimm, Yu-Li Su, Simon Chowdhury, Christopher Hocking, Eugen Plas, Scott North, Niels Viggo Jensen, Christine Theodore, Florian Imkamp, Avivit Peer, Takashi Kobayashi, Hideki Sakai, Naoto Sassa, Kazuhiro Yoshimura, Maureen Aarts, Ana Ferreira Castro, Marlen Topuzov, Juan Francisco Rodriguez, Federico Jose Vazquez, Yu-Chieh Tsai, Simon Crabb, Syed Hussain, Johanna Bendell, Marine Gross-Goupil, Gravis Gwenaelle, Raanan Berger, Galina Statsenko, Linda Evans, Alexandra Drakaki, Bradley Somer, Ian Davis, James Lynam, Giuliano Borges, Aldo Dettino, André P. Fay, Graziella Martins, Luis Eduardo Zucca, Mads Agerbaek, Haralambos Kalofonos, Eli Rosenbaum, Hideki Enokida, Hiroaki Kikukawa, Kazuo Nishimura, Satoshi Tamada, Motohide Uemura, Yamil Lopez, Jourik Gietema, Marcin Slojewski, Isabel Fernandes, Alexey Smolin, Danish Mazhar, Arash Rezazadeh Kalebasty, Bradley Carthon, Wolfgang Loidl, Fabio Franke, Gustavo Girotto, Nimira Alimohamed, Robyn Macfarlane, Helle Pappot, Guenter Niegisch, Dimitrios Mavroudis, Avishay Sella, Camillo Porta, Shin Ebara, Motonobu Nakamura, Wataru Obara, Norihiko Okuno, Nobuo Shinohara, Mikio Sugimoto, Akitaka Suzuki, Noriaki Tokuda, Hiroji Uemura, Akito Yamaguchi, Francisco Ramirez, Pawel Rozanowski, Pawel Wiechno, Bhumsuk Keam, Nikolay Kislov, Denis Plaksin, Irfan Cicin, Satish Kumar, Matthew D. Galsky, Daniel P. Petrylak, Joseph Rosales, Ulka Vaishampayan, Stephane Culine, Christos Papandreou, Taketoshi Nara, Mustafa Erman, Laurence Kreiger, Juliana Janoski, Diogo Rosa, Mariana Siqueira, Christina Canil, Lisa Sengelov, Jean-Marc Tourani, Gaku Arai, Katsuyoshi Hashine, Mutsushi Kawakita, Noboru Nakaigawa, Hayahito Nomi, Hiroaki Shiina, Hiroyoshi Suzuki, Junji Yonese, Roberto Kuri, Eleazar Macedo, Samuel Rivera, Alberto Villalobos Prieto, Anna Polakiewicz-Gilowska, Renata Zaucha, Fabio Lopes, Roman Ponomarev, Mark Pomerantz, Shahrokh Shariat, Cynthia Luk, Krzysztof Lesniewski-Kmak
Publikováno v:
lancet oncology, 21(12), 1574-1588. Lancet Publishing Group
Lancet Oncology, 21(12), 1574-1588. Lancet Publishing Group
DANUBE study investigators & Voortman, J 2020, ' Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial ', Lancet Oncology, vol. 21, no. 12, pp. 1574-1588 . https://doi.org/10.1016/S1470-2045(20)30541-6
The Lancet Oncology, 21(12), 1574-1588. ELSEVIER SCIENCE INC
Lancet Oncology, 21(12), 1574-1588. Lancet Publishing Group
DANUBE study investigators & Voortman, J 2020, ' Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial ', Lancet Oncology, vol. 21, no. 12, pp. 1574-1588 . https://doi.org/10.1016/S1470-2045(20)30541-6
The Lancet Oncology, 21(12), 1574-1588. ELSEVIER SCIENCE INC
Background: Survival outcomes are poor for patients with metastatic urothelial carcinoma who receive standard, first-line, platinum-based chemotherapy. We assessed the overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or
Autor:
Jean-Christophe Eymard, Cora N. Sternberg, Ásgerður Sverrisdóttir, Carole Helissey, Roberto Iacovelli, Ronald de Wit, Ayse Ozatilgan, Christine Theodore, Daniel Castellano, Christine Geffriaud-Ricouard, Bertrand Tombal, Bohuslav Melichar, Johann S. de Bono, Joan Carles, Gero Kramer, Michail Liontos, Christian Wülfing, Susan Feyerabend, Karim Fizazi
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:The results of the CARD (NCT02485691) study demonstrated superiority of cabazitaxel (CBZ) vs abiraterone or enzalutamide in patients with metastatic castration-resistant ...
Autor:
Pernelle Lavaud, Etienne Suc, Gwenaelle Gravis, Alain Ravaud, Gael Deplanque, Igor Latorzeff, Florence Joly, Nicole Tubiana-Mathieu, Muriel Habibian, Jean-Marie Boher, Brigitte Laguerre, Christian Platini, Stéphane Oudard, Jean Marc Ferrero, Jean-François Berdah, Stéphane Culine, Frederic Rolland, Frank Priou, Clemence Legoupil, Damien Pouessel, Ivan Krakowski, Philippe Beuzeboc, Ali Hasbini, Jérôme Dauba, Jean-Christophe Eymard, Claude El Kouri, Marjorie Baciuchka, Stéphanie Foulon, Remy Delva, Loic Mourey, Michel Soulié, Claude Linassier, Guilhem Bousquet, Christine Theodore, Sylvie Zanetta, Gabrielle Tergemina-Clain, Karim Fizazi, Jean-Pascal Machiels
Publikováno v:
European Urology
European Urology, 2017, ⟨10.1016/j.eururo.2017.09.022⟩
European Urology, 2017, ⟨10.1016/j.eururo.2017.09.022⟩
Background Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE. No data are available on the efficac
Autor:
Anne-Laure Martin, Gwenaelle Gravis, J. P. Malhaire, G. Le Teuff, Frederic Rolland, J.-C. Eymard, M. Reckova, F. Journeau, Aude Flechon, Lance C. Pagliaro, Muriel Habibian, Jozef Mardiak, Stéphane Culine, Karim Fizazi, Christopher J. Logothetis, Yohann Loriot, P. Kerbrat, Christine Chevreau, Guilhem Roubaud, A. Laplanche, Remy Delva, Claude Linassier, Christine Theodore, Lionnel Geoffrois
Publikováno v:
European Journal of Cancer. 87:140-146
Background The GETUG 13 phase III trial tested personalised chemotherapy based on tumour marker decline in patients with poor-prognosis germ-cell tumour (GCT) and demonstrated that a dose-dense regimen improves progression-free survival in patients w
Autor:
Ásgerður Sverrisdóttir, Gero Kramer, Aristotle Bamias, R. de Wit, Ayse Ozatilgan, Cora N. Sternberg, Bohuslav Melichar, M.C. Foster, J.S. de Bono, Roberto Iacovelli, Susan Feyerabend, Christian Wülfing, Carole Helissey, Christine Geffriaud-Ricouard, Bertrand Tombal, Daniel Castellano, Joan Carles, Christine Theodore, J.-C. Eymard, Karim Fizazi
Publikováno v:
ESMO Open, 6(5):100241. BMJ Publishing Group
Scientia
ESMO Open
ESMO open, Vol. 6, no. 5, p. 100241 [1-9] (2021)
Scientia
ESMO Open
ESMO open, Vol. 6, no. 5, p. 100241 [1-9] (2021)
Background There is growing evidence that a high neutrophil-to-lymphocyte ratio (NLR) is associated with poor overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC). In the CARD study (NCT02485691), cabazitaxe
Autor:
Jozef Mardiak, Remy Delva, N. Naoun, J. P. Malhaire, Frederic Rolland, G. Le Teuff, S. Nenan, Stéphane Culine, Christine Chevreau, Lionnel Geoffrois, J.-C. Eymard, Gwenaelle Gravis, M. Reckova, Karim Fizazi, P. Kerbrat, Aude Flechon, Luigi Pagliaro, Guilhem Roubaud, Christine Theodore, Claude Linassier
Publikováno v:
Annals of Oncology. 32:S719